Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis.

ABSTRACT:

Background

Uncontrolled T-cell activation plays a key role in systemic sclerosis (SSc). Arsenic trioxide (ATO) has immunological effects and has demonstrated potential in preclinical SSc models. In this study, we assessed the efficacy of ATO in Fra2 transgenic (Fra2^TG) mice, which develop severe vascular remodeling of pulmonary arterioles and nonspecific interstitial pneumonia-like lung disease, closely resembling human SSc-associated pulmonary hypertension, therefore partially resembling to the SSc human disease.

Methods

The efficacy of ATO in Fra2^TG mice was evaluated through histological scoring and determination of cell infiltration. Fibrotic changes in the lungs were assessed by measuring collagen content biochemically, using second harmonic genera

SUBMITTER: Cauvet A 

PROVIDER: S-EPMC10496169 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature